Joseph Beaulieu
Keine laufenden Positionen mehr
Karriereverlauf von Joseph Beaulieu
Ehemalige bekannte Positionen von Joseph Beaulieu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EPIZYME, INC. | Comptroller/Controller/Auditor | 01.07.2018 | 01.02.2023 |
Treasurer | 01.07.2018 | - | |
Morningstar, Inc. (Research)
Morningstar, Inc. (Research) Investment ManagersFinance Morningstar, Inc. (Research) is the investment research arm of Morningstar, Inc. (NASDAQ: MORN), an American financial services firm headquartered in Chicago, Illinois. The firm was founded by Joseph Mansueto in 1984 and provides independent portfolio information offering star ratings and analysis of managed funds. They also provide economic commentary and asset allocation information based on qualitative research. | Analyst-Equity | 01.05.2009 | 31.08.2011 |
Direktor der Forschung - Eigenkapital | 01.05.2009 | 31.08.2011 | |
ABN AMRO Securities (USA), Inc. | Analyst-Equity | 31.10.1999 | 31.10.1999 |
Ausbildung von Joseph Beaulieu
The University of Chicago | Undergraduate Degree |
University of Illinois | Graduate Degree |
Wallace E Carroll School of Management | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Analyst-Equity | 2 |
Undergraduate Degree | 2 |
Director of Research - Equity | 1 |
Sektoral
Consumer Services | 4 |
Finance | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Morningstar, Inc. (Research)
Morningstar, Inc. (Research) Investment ManagersFinance Morningstar, Inc. (Research) is the investment research arm of Morningstar, Inc. (NASDAQ: MORN), an American financial services firm headquartered in Chicago, Illinois. The firm was founded by Joseph Mansueto in 1984 and provides independent portfolio information offering star ratings and analysis of managed funds. They also provide economic commentary and asset allocation information based on qualitative research. | Finance |
ABN AMRO Securities (USA), Inc. | Finance |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Joseph Beaulieu
- Erfahrung